Velia Therapeutics has announced it is winding down its operations while staying loyal to the therapeutic potential of ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday and set a ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on January 7 and set a price ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Halozyme (HALO – Research Report), with a price ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed ... head of Merck Research Laboratories. "Novel HIV treatment options that allow for less frequent ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Gilead’s CAR-T cancer therapy has been approved ... this is not a foregone conclusion when the economic model behind CAR-Ts is as novel as its science.